Biocon Biologics launches biosimilar
Etanercept is a fusion-protein that inhibits tumor necrosis factor (TNF) and is used in the treatment of autoimmune diseases like rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.
Since receiving EU marketing authorization in 2020, Nepexto has earned broad adoption across Europe. Following the 2022 acquisition and vertical integration of the biosimilars business globally, Biocon Biologics is building on the solid foundation to strategically expand Nepexto into new markets worldwide and further strengthen the company's immunology offering.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
2 days ago
- New Indian Express
Rotary to organise CPR camps, health checkups for frontline cops
BENGALURU: The June 4 stampede at Chinnaswamy Stadium that claimed 11 lives and left several police personnel injured, has shaken up Karnataka. There is a call by senior officers and civic leaders to train police and citizens in the skill of cardiopulmonary resuscitation (CPR). Throwing light on the toll law enforcement officers paid during the stampede, ADGP KV Sharath Chandra said, 'Our men and women in uniform need to be trained not just in riot control but in reviving a life. CPR is useful for both police and people.' Now, with heart attacks increasing among people in their 20s and 30s, CPR literacy has become essential. Rotary Bangalore Northwest has pledged to organize CPR training and health checkups for frontline police, especially armed and civil forces deployed on high-stress bandobast duty. Former police commissioner Bhaskar Rao, advising the public to step up during medical emergencies, said, 'Every second counts. You don't need a uniform to save a life, just training and courage.' Lakshmi Achuta, president of Rotary Bangalore Northwest and Principal Strategic Adviser, Biotech, at Biocon, said it is not enough to train only the police. 'Imagine how many lives could have been saved at the KSCA stampede if more people in the crowd knew CPR. It is about empowering everyone with a life-saving skill.' The movement has also gone global. Rajiv Thalla, based in the United States, has turned a personal heartbreak into a mission. After losing his 23-year-old son Rohan Rajiv to a sudden heart attack, he has taken it on himself to hold free CPR demonstrations, to ensure others don't suffer the same fate. He travels across cities, from Los Angeles to Lucknow, distributing educational material, and partnering with Rotary. His younger son, a doctor, stands by him. 'This isn't just about first aid, but first response. A few minutes can mean the difference between life and death. CPR gives you those minutes.'
Time of India
4 days ago
- Time of India
Syngene International reports 11% revenue growth and 59% net profit surge in Q1
Synopsis Syngene International, a Biocon subsidiary, reveals an 11% revenue increase to Rs 875 crore for the first quarter. Net profit jumps 59% to Rs 87 crore. Growth is attributed to research services and biologics manufacturing. Operations commenced at Unit III in Bengaluru. Preparations advance for the Bayview facility in the US.
Time of India
4 days ago
- Time of India
Syngene Q1 profit up 59% to Rs 87 crore
Representative image BENGALURU: Syngene International, a subsidairy of Biocon , reported a 59 per cent year-on-year increase in profit after tax to Rs 87 crore in the first quarter ended June 2025, aided by revenue growth and a tax benefit from the transfer of gratuity funds to an employee trust. Revenue from operations rose 11 per cent to Rs 875 crore during the period. Ebitda grew 19 per cent year-on-year to Rs 224 crore, with margins improving to 25 per cent from 23 per cent a year earlier. CEO Peter Bains said the growth was led by the conversion of pilot programs into long-term contracts in the Research Services division. The company also progressed operations at its Biologics Unit III facility in Bengaluru and prepared for the launch of its Bayview site in the US later this year. It commissioned a new peptide laboratory during the quarter. The company said it underwent over 20 client and regulatory audits in Q1, including a USFDA GCP inspection of its Human Pharmacology Unit with no observations. Its Biologics facility received an Establishment Inspection Report with a Voluntary Action Indicated outcome. CFO Deepak Jain said operating Ebitda margins held around 24 per cent, supported by revenue growth and cost optimisation. Syngene said it remains on track to meet its full-year guidance. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
